Gilead is also developing new medicines for chronic hepatitis C virus (HCV) infection, devoting approximately one third of its R&D budget to this area. HCV affects about 185 million people worldwide and is the leading cause of liver cancer and transplantation in the United States. 2, 3 In 2013, the company's first hepatitis C medicine received U.S. regulatory approval, offering high cure rates and shortened duration of therapy, and reducing or eliminating the need for interferon injections for many patients. Gilead continues to develop new HCV therapies, including fixed-dose combination regimens, to further improve treatment for the disease.
Developing world research
Because a number of Gilead's medicines treat diseases, such as HIV and viral hepatitis, which disproportionately impact patients in the developing world, the company makes it a priority to support high-quality medical research conducted in resource-limited countries. By focusing research on the populations most likely to benefit from our medicines, Gilead is able to optimize treatment delivery in resource-limited settings while also building local research capacity and expertise. Through the Gilead Foundation, the company also supports mentorship programs that link scientists, medical professionals and students in the developing world with their peers in developed countries.
